Bayer Reports Data from the P-III (OASIS 3) Trial of Elinzanetant for Treating Vasomotor Symptoms in Postmenopausal Women
Shots:
- The P-III (OASIS 3) trial assesses elinzanetant’s (120mg, oral, QD) safety & efficacy vs PBO to treat vasomotor symptoms in postmenopausal women (n=628, 40yrs. to 65yrs.) over 52wks. in 83 sites across 9 countries
- The study reached its 1EP depicting the reduced frequency of moderate to severe vasomotor symptoms from baseline to wk.12 and a consistent safety profile with prior studies was seen over 52wks.
- Additionally, Bayer previously reported results from the 2 P-III (OASIS 1 & OASIS 2) programs that reached the 1EPs and 2EPs. The results from all three studies will be highlighted at future scientific congresses and will form the basis of marketing authorizations for elinzanetant to treat VMS
Ref: Bayer | Image: Bayer
Related News:- Bayer Partners with Aignostics to Strengthen its Precision Oncology Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
